Hologic showcases new Mammosite at ASTRO 2009

Article

A version of Hologic’s partial breast irradiation device, the MammoSite ML, took center stage this week at the American Society for Therapeutic Radiology and Oncology meeting.

A version of Hologic’s partial breast irradiation device, the MammoSite ML, took center stage this week at the American Society for Therapeutic Radiology and Oncology meeting. The multi-lumen configuration, cleared by the FDA on August 27, allows oncologists to shape the radiation dose. It is the latest enhancement of the basic design, commercially launched some seven years ago. MammoSite delivers targeted radiation therapy directly to the area where cancer is most likely to recur. A full course of radiation can be delivered in just five days. The approach minimizes radiation exposure of healthy tissue surrounding the target site, minimizing side effects such as skin discoloration and scarring, burning, fatigue, and damage to surrounding organs.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.